Introduction: The use of anthracycline antibiotics in adult acute lymphoblastic leukemia (ALL) has resulted in an improved outcome to remission induction therapy. However,the exact role of these drugs in consolidation therapy is less clear, especially in specific ALL subsets. Materials and methods: A retrospective analysis was conducted on the outcome of 308 patients (median age 35 years, range 13-75) with the most frequent subtype, early-B ALL, treated between 1974 and 1998 on eight consecutive protocols. Anthracycline-related effects were assessed by evaluating the impact of planned anthracycline dose-intensity (A-DI) on long-term outcome. A-DI (in mg/m2/week) during the first twelve weeks of consolidation therapy was classified as either 'high' (doxorubicin > 20, idarubicin > 7) or 'low'. Results: Complete remission was achieved in 78% of cases. With a median follow-up of 6.5 years, on multivariate analysis, disease-free survival (DFS) correlated only with expression of the Philadelphia (Ph) chromosome and/or associated BCR-ABL rearrangements (Ph/BCR+) (P=0.0001) and planned A-DI (P<0.0001). On this basis, four major prognostic groups with significantly different DFS could be identified: (1) Ph/BCR-, 'high' A-DI (n=102), median 3.5 years and 41% at five years, respectively; (2) Ph/BCR-, 'low' A-DI (n=64), 1.3 years and 16%; (3) Ph/BCR+, 'high' A-DI (n=35), 1.7 years and 20%; (4) Ph/BCR+, 'low' A-DI (n=39), 0.75 years and 0%. When analyzed separately for Ph/BCR- (n=166) and Ph/BCR+ (n=74) patients, the A-DI effect on DFS was preserved in the former (P=0.018) whereas, in Ph/BCR+ patients, only age <50 years (P=0.004) and blast count <25×109/1 (P=0.02) correlated with better DFS. However, Ph/BCR+ patients with the best prognostic profile (age <50 years and blast count <25×109/1; n=21) who were treated on 'high' A-DI regimens experienced a median DFS of 2.2 years with DFS 21% at five years, compared to 0.67-1 years and 0-10% in other cases (n=53, P<0.01). Conclusion: A 'high' A-DI may act as a positive treatment-related prognostic factor in early B-lineage ALL. Although mainly restricted to patients with Ph/BCR- ALL, A-DI could also influence the outcome in Ph/BCR+ patients with other favorable prognostic factors.

Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia / R. Bassan, A.Z. Rohatiner, T. Lerede, E. Di Bona, A. Rambaldi, E. Pogliani, G. Rossi, P. Fabris, S. Morandi, P. Casula, M. Carter, G. Lambertenghi-Deliliers, T.A. Lister, T. Barbui. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 1:4(2000), pp. 226-234.

Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia

A. Rambaldi;G. Lambertenghi-Deliliers;
2000

Abstract

Introduction: The use of anthracycline antibiotics in adult acute lymphoblastic leukemia (ALL) has resulted in an improved outcome to remission induction therapy. However,the exact role of these drugs in consolidation therapy is less clear, especially in specific ALL subsets. Materials and methods: A retrospective analysis was conducted on the outcome of 308 patients (median age 35 years, range 13-75) with the most frequent subtype, early-B ALL, treated between 1974 and 1998 on eight consecutive protocols. Anthracycline-related effects were assessed by evaluating the impact of planned anthracycline dose-intensity (A-DI) on long-term outcome. A-DI (in mg/m2/week) during the first twelve weeks of consolidation therapy was classified as either 'high' (doxorubicin > 20, idarubicin > 7) or 'low'. Results: Complete remission was achieved in 78% of cases. With a median follow-up of 6.5 years, on multivariate analysis, disease-free survival (DFS) correlated only with expression of the Philadelphia (Ph) chromosome and/or associated BCR-ABL rearrangements (Ph/BCR+) (P=0.0001) and planned A-DI (P<0.0001). On this basis, four major prognostic groups with significantly different DFS could be identified: (1) Ph/BCR-, 'high' A-DI (n=102), median 3.5 years and 41% at five years, respectively; (2) Ph/BCR-, 'low' A-DI (n=64), 1.3 years and 16%; (3) Ph/BCR+, 'high' A-DI (n=35), 1.7 years and 20%; (4) Ph/BCR+, 'low' A-DI (n=39), 0.75 years and 0%. When analyzed separately for Ph/BCR- (n=166) and Ph/BCR+ (n=74) patients, the A-DI effect on DFS was preserved in the former (P=0.018) whereas, in Ph/BCR+ patients, only age <50 years (P=0.004) and blast count <25×109/1 (P=0.02) correlated with better DFS. However, Ph/BCR+ patients with the best prognostic profile (age <50 years and blast count <25×109/1; n=21) who were treated on 'high' A-DI regimens experienced a median DFS of 2.2 years with DFS 21% at five years, compared to 0.67-1 years and 0-10% in other cases (n=53, P<0.01). Conclusion: A 'high' A-DI may act as a positive treatment-related prognostic factor in early B-lineage ALL. Although mainly restricted to patients with Ph/BCR- ALL, A-DI could also influence the outcome in Ph/BCR+ patients with other favorable prognostic factors.
ALL; Anthracyclines; Ph/BCR-ABL status; Remission duration
Settore MED/09 - Medicina Interna
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/47271
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? ND
social impact